Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review

Fukuda, Izumi

doi:10.1272/jnms.jnms.2023_90-215

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, early diagnosis of hypophysitis and initiation of appropriate treatment are crucial. [9] As a publicly available database of spontaneous adverse event reports submitted to the FDA by healthcare professionals, consumers and manufacturers, the FDA Adverse Event Reporting System (FAERS) database enables early detection of safety signals, prompt characterization of safety profiles that necessitate reevaluation of risks and benefits, and interim drug-to-drug comparisons between drugs in the same therapeutic class. [10] To this end, with nivolumab, pembrolizumab, ipilimumab, and atezolizumab serving as the target drugs, we analyzed the relationship between these drugs and adverse events in hypophysitis (including lymphocytic hypophysitis), using relevant data from the FAERS database.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database

Tang,

Han,

Song

et al. 2024

Medicine

View full text Add to dashboard Cite

The use of immune checkpoint inhibitor (ICI) marked a revolutionary change in cancer treatment and opened new avenues for cancer therapy, but ICI can also trigger immune-related adverse events (irAEs). Here, we investigated the publicly available US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to gain insight into the possible association between immune checkpoint inhibitors and hypophysitis. Data on adverse events (AEs) due to hypophysitisfor nivolumab, pembrolizumab, ipilimumab, and atezolizumab were collected from the US FDA Adverse Event Reporting System from the first quarter of 2004 to the second quarter of 2021, and the signals for hypophysitis associated with the four drugs were examined using the reporting odds ratio (ROR) method. The number of reported hypophysitis events ≥ 3 and the lower limit of the 95% confidence interval (CI) of the ROR > 1 were considered positive for hypophysitis signals. A total of 1252 AE reports of hypophysitis associated with nivolumab, pembrolizumab, ipilimumab, and atezolizumab were collected, including 419, 149, 643, and 41 cases, respectively. The RORs of hypophysitis were 289.58 (95% CI 258.49–324.40), 171.74 (95% CI 144.91–203.54), 2248.57 (95% CI 2025.31–2496.45), and 97.29 (95% CI 71.28–132.79), respectively. All four drugs were statistically correlated with the target AE, with the correlation being, in descending order, ipilimumab, nivolumab, pembrolizumab, and atezolizumab. Nivolumab, pembrolizumab, ipilimumab, and atezolizumab have all been associated with hypophysitis, which can negatively impact quality of life, and early recognition and management of immune checkpoint inhibitor-related hypophysitis is critical.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Therefore, early diagnosis of hypophysitis and initiation of appropriate treatment are crucial. [ 9 ]…”

Section: Introductionmentioning

confidence: 99%

The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database

Tang,

Han,

Song

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

Novel Cancer Therapeutics: Perioperative Implications and Challenges

Gutierrez,

Rajendram,

Idowu

2024

Anesthesia &Amp; Analgesia

View full text Add to dashboard Cite

Since the introduction of immunotherapy and targeted therapies, patients not only have adequate tumoral response to these treatments, but their quality of life has improved due to milder toxicities. However, due to their wide mechanisms of action, the toxicity profile for these therapies is broad, can have an insidious onset, and their recognition can be challenging. Rarely, some of these toxicities can cause significant morbidity if not diagnosed early and lead to intensive care unit (ICU) admission and death. Anesthesiologists are likely to encounter not only a wide spectrum of these toxicities but also a wide range of severity. In some cases, they could be the first to make the diagnosis and therefore need to be prepared to rapidly assess, establish differentials, perform a diagnostic workup, and evaluate the impact the toxicity could have on the patients’ care during the perioperative period. In this article, we set to review toxicities of novel cancer therapies such as checkpoint inhibitors and targeted therapies, that could present in the perioperative setting. This article will help as a guide for anesthesiologists to recognize their clinical presentation, the approach to their diagnosis, and their impact on patient care.

show abstract

Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review

Cited by 2 publications

References 25 publications

The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database

The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database

Novel Cancer Therapeutics: Perioperative Implications and Challenges

Contact Info

Product

Resources

About